Denali deals reflect confidence in neurodegenerative disease space
Privately-held US biotech Denali Therapeutics has announced a series of previously undisclosed collaborations and licensing deals – including an agreement with Genentech, a unit of Swiss pharma giant Roche (ROG: SIX), over a Parkinson’s disease treatment.
A deal with UK-based biotech firm F-star on antibodies for the delivery of medicines across the blood-brain barrier (BBB) into the central nervous system (CNS) which could see Denali pay a total of $1 billion, is just one of several collaborations revealed.
Denali is developing a diverse portfolio, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze